/Dexcom%20Inc%20HQ-by%20JHVEPhoto%20via%20Shutterstock.jpg)
DexCom, Inc. (DXCM), a San Diego-based medical device company with a $32.5 billion market cap, specializes in continuous glucose monitoring (CGM) systems. Its technology includes a small, implantable sensor that tracks glucose levels beneath the skin and transmits data to an external receiver in real-time. DexCom is slated to report its fiscal 2025 second-quarter earnings after the market closes on Wednesday, July 30.
Ahead of the event, analysts expect DXCM to report a profit of $0.45 per share on a diluted basis, up 4.7% from $0.43 per share in the year-ago quarter. The company beat the consensus estimates in two of the last four quarters while missing the forecast on two other occasions.